Blood test may predict ovarian cancer relapse without surgery
NCT ID NCT04511988
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times
Summary
This study tests whether a blood test (liquid biopsy) can be used instead of multiple tissue samples to see how ovarian cancer changes over time. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to 2 years. The goal is to see if the amount of tumor DNA in the blood can predict relapse, progression, or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, 54506, France
Conditions
Explore the condition pages connected to this study.